Vitamin D and estrogen have already shown well-documented results in improving bone health in women. A new study from China suggests that this same combination could help prevent metabolic syndrome, a constellation of conditions that increases the risk of heart disease, stroke, and diabetes in postmenopausal women. Results are published online in Menopause, the journal … Read more
Study finds moderate weight loss reduces levels of sex hormones linked to breast cancer risk – Even a moderate amount of weight loss can significantly reduce levels of circulating estrogens that are associated with an increased risk of breast cancer, revealed by researchers at Fred Hutchinson Cancer Research Center.
Pfizer Announces Voluntary Nationwide Recall Of Lo/Ovral?-28 And Norgestrel/Ethinyl Estradiol Tablets Due To Possibility Of Inexact Tablet Counts Or Out Of Sequence Tablets – Pfizer Inc. announced that it has voluntarily recalled 14 lots of Lo/Ovral?-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic)for customers in the U.S. market.
BPA may cause heart disease in women, research shows – New research by a team of scientists at the University of Cincinnati (UC) shows that bisphenol A (BPA) may be harmful for the heart, particularly in women. Results of several studies are being presented in Washington, D.C., at ENDO 09, the Endocrine Society’s annual meeting, June 10-13.
Long-term sun exposure hinder the ability of topical estradiol to stimulate collagen production in aged human skin. – Treating the skin with estrogen can stimulate collagen production-which improves the appearance of the skin-in areas not typically exposed to the sun, according to new research from the University of Michigan Health System.
Ortho Women?s Health & Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., has updated the prescribing information for ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system) to include further epidemiologic data. – The U.S. Food and Drug Administration (FDA) approved additional changes to the Ortho Evra Contraceptive Transdermal (Skin) Patch label to include the results of a new epidemiology study that found that users of the birth control patch were at higher risk of developing serious blood clots, also known as venous thromboembolism (VTE), than women using birth control pills. VTE can lead to pulmonary embolism.